Difficulties and advance of CAR-T therapy in hepatocellular carcinoma

Siyu Zhu

doi:10.1117/12.2669678

24 March 2023 Difficulties and advance of CAR-T therapy in hepatocellular carcinoma

Siyu Zhu

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126113P (2023) https://doi.org/10.1117/12.2669678
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Primary hepatic carcinoma belongs to the malignant tumors that appear most commonly in the world, among which hepatocellular carcinoma (HCC) accounts for 85%-90%, with high frequency and mortality. At present, the main treatment for liver cancer still focuses on surgical resection or transplantation. However, due to its poor recovery and easy recurrence and metastasis, it is necessary to find other adjuvant therapies based on surgical treatment to try to cure primary liver cancer. Chimeric Antigen Receptor - T cell (CAR-T) therapy is emerging immunotherapy in recent years. Constructing specific CAR structures in vitro, then directing T cells to recognize antigen in vivo, while a variety of effectors can be released to kill tumor cells through immune action. Among them, CAR-T therapy has achieved great success dealing with hematological tumors. Nevertheless, because of the heterogeneity and tumor microenvironment (TME) of solid tumors, it’s difficult to use CAR-T therapy effectively in clinical treatment. Therefore, here we summarize the problems CAR-T therapy facing in curing HCC, as well as some solutions and breakthroughs, hoping to play a certain role in further applying CAR-T therapy in HCC clinical treatment in the future.

Citation Download Citation

Siyu Zhu "Difficulties and advance of CAR-T therapy in hepatocellular carcinoma", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126113P (24 March 2023); https://doi.org/10.1117/12.2669678

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available